Company profile: Blackrock Neurotech
1.1 - Company Overview
Company description
- Provider of brain-computer interface technology and manufacturing, offering implantable clinical solutions and tools including the Utah Array for neural recording and stimulation; NeuroPort BCI to control prosthetics and regain motor functions; Wireless iBCI for high-bandwidth remote neural signals; and a cortical neuroprosthetic that provides artificial vision via neural stimulation.
Products and services
- NeuroPort BCI: Modular clinical system that decodes neural signals to operate prosthetics and restore motor functions, delivering direct control of assistive devices from brain activity
- Utah Array: Clinical-grade BCI device enabling neural recording and stimulation to translate motor intent into commands for controlling external devices directly through thought
- Wireless iBCI: High-bandwidth BCI that transmits neural signals for remote use, enabling untethered data streaming without physical cabling
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Blackrock Neurotech
NKGen Biotech
HQ: United States
Website
- Description: Provider of natural killer (NK) cell therapy candidates to restore immune function for cancer treatment, including SNK01, an autologous NK therapy in clinical trials for neurodegenerative diseases and various cancers, and SNK02, an allogeneic NK therapy being tested for solid tumors, plus an Expanded Access Program enabling access to investigational therapies under specific conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NKGen Biotech company profile →
Minerva Neurosciences
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical product candidates for central nervous system diseases, including roluperidone (MIN-101) for negative symptoms of schizophrenia targeting serotonin, sigma, and alpha-adrenergic receptors, and MIN-301, a recombinant neuregulin-1β1 in preclinical development for Parkinson’s disease aimed at restoring brain tissue damage and improving motor function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Minerva Neurosciences company profile →
Proximagen
HQ: United Kingdom
Website
- Description: Provider of neuroscience research and drug development targeting neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease; publicly traded.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proximagen company profile →
Cenes
HQ: United Kingdom
Website
- Description: Provider of biopharmaceutical products, developing and commercializing drugs for pain control, sedation, and other central nervous system disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cenes company profile →
Neuronetics
HQ: United States
Website
- Description: Provider of non-drug, non-invasive TMS therapies for mental health, including NeuroStar Advanced Therapy for major depressive disorder using precise magnetic stimulation, supported by the TrakStar HIPAA-compliant practice management system and features like MT Assist and Contact Sensing for accurate dosing and real-time treatment feedback.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neuronetics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Blackrock Neurotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Blackrock Neurotech
2.2 - Growth funds investing in similar companies to Blackrock Neurotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Blackrock Neurotech
4.2 - Public trading comparable groups for Blackrock Neurotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →